¼¼°èÀÇ ¾È°ú¿ë ÀǾàǰ ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® : ¾à¹° Á¾·ùº°, Áúȯº°, Åõ¿© ¹æ¹ýº°, Åõ¿© °æ·Îº°, Á¦Ç° Á¾·ùº°, ÀǾàǰ Á¾·ùº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Ophthalmic Drugs Market Size, Share & Trends Analysis Report By Drug Class (Steroidal drugs, Anti-VEGF Agents), By Disease, By Dosage Form, By Route of Administration, By Product Type, By Drug Type, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1678487
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 150 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¾È°ú¿ë ÀǾàǰ ½ÃÀå ¼ºÀå°ú µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é, ¼¼°è ¾È°ú¿ë ÀǾàǰ ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 620¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2025³âºÎÅÍ 2030³â±îÁö 8.5%ÀÇ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾È°ú Áúȯ¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö°í ¾È°ú¿ë ÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â °ÍÀÌ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ¿äÀÎÀÔ´Ï´Ù. ¶ÇÇÑ, ³ëÈ­¼º Ȳ¹Ýº¯¼º, ¹é³»Àå, ¾È±¸°ÇÁ¶Áõ, ´ç´¢¸Á¸·º´Áõ, ³ì³»Àå µî ¾È°ú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¾È°ú¿ë ÀǾàǰÀÇ ¼ö¿ä¸¦ Áõ°¡½Ãų °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

BrightFocus Foundation¿¡ µû¸£¸é, 2021³â¿¡´Â 300¸¸ ¸í ÀÌ»óÀÇ ¹Ì±¹ÀÎÀÌ ³ì³»ÀåÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, ±× Áß 270¸¸ ¸í ÀÌ»óÀÌ °¡Àå ÈçÇÑ À¯ÇüÀÇ ³ì³»Àå, Áï °³¹æ°¢ ³ì³»ÀåÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¶ÇÇÑ, ¹Ì±¹¿¡¼­´Â 330¸¸ ¸íÀÌ ½Ç¸íÀ̳ª ¾à½ÃÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ³ì³»Àå ¹× ½Ç¸íÀÇ ÁÖ¿ä À§ÇèÀÎÀڷδ °í·É, °¡Á··Â, ¾ãÀº °¢¸·, ³ôÀº ¾È¾Ð µîÀ» µé ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ¾È°ú¿ë ÀǾàǰ¿¡ ´ëÇÑ Æø³ÐÀº Àα¸ ±â¹ÝÀÌ Çü¼ºµÇ¾î ÀÖ¾î À¯¸®ÇÑ ¼ºÀåÀÌ È®½Ç½ÃµÇ°í ÀÖ½À´Ï´Ù.

¶ÇÇÑ, ¾È°ú Ä¡·á ¹× ¾à¹°Àü´Þ ±â¾÷µéÀº ½Å¾à °³¹ß ±â¼ú ¹ßÀüÀ» À§ÇÑ ¿¬±¸ °³¹ßÀ» ÃËÁøÇϱâ À§ÇØ ÀÚ±Ý Áö¿øÀ» ¹Þ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¿¹¸¦ µé¾î, 2020³â 6¿ù Re-Vana Therapeutics´Â Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, Techstart Ventures LLP µîÀ¸·ÎºÎÅÍ ½Ã¸®Áî A·Î 325¸¸ ´Þ·¯ÀÇ ÅõÀÚ¸¦ À¯Ä¡Çß½À´Ï´Ù. À̹ø ÅõÀÚ À¯Ä¡·Î ¸®¹Ù³ª Å×¶óǻƽ½ºÀÇ EyeLief¿Í OcuLiefÀÇ »ýºÐÇØ¼º ±â¼ú °³¹ßÀÌ °¡¼ÓÈ­µÇ¾î ÀúºÐÀÚ ¹× »ý¹°ÇÐÀû Á¦Á¦ Àü´Þ¿¡ »ç¿ëµÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.

Safe Eyes America¿¡ µû¸£¸é ¾È°ú ÁúȯÀÇ °¡Àå ÈçÇÑ À§Çè ¿äÀÎÀº °í·É, °¡Á··Â, ´ç´¢º´, °íÇ÷¾Ð µîÀ̸ç, ³ëÀÎ Àα¸ÀÇ Áõ°¡°¡ ¾È°ú¿ë ÀǾàǰ ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, America's HEALTH RANKINGS senior report 2021¿¡ µû¸£¸é ¹Ì±¹¿¡´Â 65¼¼ ÀÌ»ó ¼ºÀÎÀÌ 5,400¸¸ ¸í ÀÌ»ó °ÅÁÖÇϰí ÀÖÀ¸¸ç, ÀÌ Àα¸´Â Àüü Àα¸ÀÇ 16.5%¸¦ Â÷ÁöÇÏ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. Ȳ¹Ýº¯¼º Á¶»ç¿¡ µû¸£¸é AMD´Â 60¼¼ ÀÌ»ó ¹Ì±¹ÀÎÀÇ ½Ç¸í ¿øÀÎ 1À§·Î ³ªÅ¸³µ½À´Ï´Ù.

¾È°ú¿ë Á¦Ç°¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¾à»ç ½ÂÀÎÀº ½ÃÀå ¼ºÀåÀ» µÞ¹ÞħÇϰí ÀÖ´Â °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, »êÅÙÁ¦¾àÀº 2022³â 6¿ù ¾È±¸°ÇÁ¶Áõ Ä¡·áÁ¦ 'µðÄí¾Æ½º LX Á¡¾È¾×'ÀÇ ÀϺ» ³» Á¦Á¶ÆÇ¸Å ½ÂÀÎÀ» ȹµæÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ Á¡¾È¾×Àº Åõ¿© Ƚ¼ö¸¦ ÁÙ¿© ȯÀÚÀÇ ¼øÀÀµµ¸¦ ³ôÀÎ °³·®Çü Á¦Á¦ÀÔ´Ï´Ù.

¾È°ú¿ë ÀǾàǰ ½ÃÀå : ºÐ¼® °³¿ä

¸ñÂ÷

Á¦1Àå ºÐ¼® ¹æ¹ý ¹× ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : ¾à¹° Á¾·ùº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : Áúȯº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : Åõ¿© °æ·Îº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : Åõ¿© ¹æ¹ýº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : Á¦Ç° Á¾·ùº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦9Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : ÀǾàǰ Á¾·ùº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦10Àå ¾È°ú¿ë ÀǾàǰ ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦11Àå °æÀï ±¸µµ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Ophthalmic Drugs Market Growth & Trends:

The global ophthalmic drugs market size is expected to reach USD 62.08 billion by 2030, garnering a CAGR of 8.5% from 2025 to 2030, according to a new report by Grand View Research, Inc. The rising awareness about ophthalmic disorders and the surge in demand for ophthalmic drugs are the factors propelling the market growth. Moreover, an increase in the prevalence of eye diseases such as age-related macular degeneration, cataract, dry eye, diabetic retinopathy, glaucoma, and others are anticipated to boost the demand for ophthalmic drugs.

According to BrightFocus Foundation in 2021, it is estimated that over 3 million Americans are living with glaucoma, and, among them over 2.7 million patients were affected by the most common type of glaucoma i.e. open-angle glaucoma. Moreover, 3.3 million people are affected by blindness and low vision in the U.S. Some of the major risk factors for glaucoma and blindness are, higher age, family history, thin cornea, and high eye pressure. This creates a wide population base for ophthalmic drugs, thereby, ensuring lucrative growth.

Furthermore, ocular therapeutic and drug delivery companies are receiving funding to expedite R&D for advancements in technologies to develop novel drugs, which is likely to fuel market growth. For instance, in June 2020, Re-Vana Therapeutics received USD 3.25 million in pre-series A funding from Qubis, ExSight Ventures, LLC, Clarendon Fund Managers, Visionary Ventures, and Techstart Ventures LLP. The funding is expected to boost the development of Re-Vana Therapeutics' EyeLief & OcuLief biodegradable technologies that can be used for a small molecule as well as biologics delivery.

Moreover, the rising geriatric population is the key driver for the ophthalmic drugs market growth. According to Safe Eyes America, the most common risk factors for ophthalmic diseases are high age, family history, diabetes, and high blood pressure. For instance, as per AMERICA's HEALTH RANKINGS senior report 2021 it was estimated that more than 54 million adults of age more than 65 live in the U.S., and that population accounted for 16.5% of the total population. According to Macular Degeneration Research AMD is the leading reason for blindness in U.S. people over the age of 60.

Ongoing regulatory approvals for ophthalmic products are likely to support market growth. For instance, in June 2022 Santen Pharmaceutical Co., Ltd announced that it has got marketing and manufacturing approval for the dry eye disease treatment DIQUAS LX ophthalmic solution in Japan. This solution is the improved formulation that has reduced dosing frequency and improved patient compliance.

Ophthalmic Drugs Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Ophthalmic Drugs Market Variables, Trends & Scope

Chapter 4. Ophthalmic Drugs Market: Drug Class Estimates & Trend Analysis

Chapter 5. Ophthalmic Drugs Market: Disease Estimates & Trend Analysis

Chapter 6. Ophthalmic Drugs Market: Route of Administration Estimates & Trend Analysis

Chapter 7. Ophthalmic Drugs Market: Dosage Type Estimates & Trend Analysis

Chapter 8. Ophthalmic Drugs Market: Product Type Estimates & Trend Analysis

Chapter 9. Ophthalmic Drugs Market: Drug Type Estimates & Trend Analysis

Chapter 10. Ophthalmic Drugs Market: Regional Estimates & Trend Analysis

Chapter 11. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â